Medication info
Albestol Tablets 1.25 mg (Nebivolol Hydrochloride)

Albestol Tablets 1.25 mg (Nebivolol Hydrochloride)

Prescription medicationTabletOral
Ingredient · strength
Nebivolol Hydrochloride›1.3625mg / 1 tablet
Manufacturer / importer
Allico Pharmaceutical Co., Ltd.
Appearance
White round tablets
Packaging
30 tablets/bottle, 300 tablets/bottle, 500 tablets/bottle
Approval status
Active

MFDS item code 202501802 · Approved 2025.07.15

Summary

Main use
Adjunctive treatment of mild to moderate chronic stable heart failure in patients aged 70 years or older
Who takes it
Adults
Adult dose
1. Chronic heart failure 1) Elderly patients aged 70 years or older This medicine should be administered to patients with chronic, stable heart failure who have had no history of acute heart failure during the previous 6 weeks. The doses of cardiovascular medicines such as diuretics, digoxin, ACE inhibitors, and angiotensin II receptor blockers should be stabilized up to 2 weeks before starting this medicine. Taking the patient's condition into account, the dose should be gradually increased at 1- to 2-week intervals until the optimal dose for the individual patient is reached. Treatment should be started with nebivolol 1.25 mg once daily and, if necessary, increased to 2.5 mg once daily, 5 mg once daily, and up to 10 mg once daily. The maximum daily dose is 10 mg. It may be taken with food. 2) Patients with renal impairment Because titration to the maximum tolerated dose is adjusted for each individual patient, dose adjustment is not necessary in patients with mild to moderate renal impairment. Do not administer to patients with severe renal impairment (serum creatinine≥250μmol/L), as there is no experience with use in these patients.

Ingredients

Manufacturer
Allico Pharmaceutical Co., Ltd.

Efficacy & effects

Adjunctive treatment of mild to moderate chronic stable heart failure in patients aged 70 years or older

  • Chronic heart failure
  • mild to moderate stable chronic heart failure
View approved original text

This medication is used adjunctively in the standard treatment of patients aged 70 and older with chronic heart failure, particularly mild to moderate stable chronic heart failure. It helps to improve heart function and alleviate symptoms, thereby enhancing the quality of life of patients. By maintaining regular use, it contributes to slowing the progression of heart failure and reducing the risk of hospitalization. This medication plays a significant role in managing chronic heart failure in elderly patients and improves overall therapeutic efficacy.

How to take

Adult dose

1. Chronic heart failure 1) Elderly patients aged 70 years or older This medicine should be administered to patients with chronic, stable heart failure who have had no history of acute heart failure during the previous 6 weeks. The doses of cardiovascular medicines such as diuretics, digoxin, ACE inhibitors, and angiotensin II receptor blockers should be stabilized up to 2 weeks before starting this medicine. Taking the patient's condition into account, the dose should be gradually increased at 1- to 2-week intervals until the optimal dose for the individual patient is reached. Treatment should be started with nebivolol 1.25 mg once daily and, if necessary, increased to 2.5 mg once daily, 5 mg once daily, and up to 10 mg once daily. The maximum daily dose is 10 mg. It may be taken with food. 2) Patients with renal impairment Because titration to the maximum tolerated dose is adjusted for each individual patient, dose adjustment is not necessary in patients with mild to moderate renal impairment. Do not administer to patients with severe renal impairment (serum creatinine≥250μmol/L), as there is no experience with use in these patients.

Precautions

This medication should not be used in certain patients. Individuals with hypersensitivity to this medication or with a history of bronchospasm or bronchial asthma may be at risk if they take this medication. Patients with metabolic acidosis, very slow heart rates (bradycardia), or cardiac conduction disorders should not take this medication. Patients with acute heart failure, cardiogenic shock, uncontrolled heart failure, or hypotension should also avoid this medication. Pregnant or nursing women and those with significant peripheral circulation disorders or severe liver impairment should not take this medication. It should also not be administered to chronic heart failure patients with severe renal failure or those with genetic conditions such as lactose intolerance. This medication must be used cautiously in patients with chronic lung disease, untreated heart failure, ischemic heart failure, or peripheral circulation disorders. Additionally, caution is needed for patients with first-degree AV block, certain forms of angina, hyperthyroidism, a history of psoriasis, diabetes patients, and the elderly. This medication may cause a variety of side effects including skin rash, vision impairment, bradycardia, hypotension, worsening heart failure, headache, dizziness, diarrhea, shortness of breath, itching, edema, and fatigue. Neuropsychiatric symptoms such as depression, nightmares, and, rarely, fainting may also occur. In severe cases, edema or vascular reactions may occur. Caution must be taken to prevent worsening of bradycardia during use, and it is advisable to discontinue the medication at least 24 hours before surgery. Blood pressure, heart rate, and cardiac function must be closely monitored after administration. This medication may interact with other drugs; caution is required when taken with calcium channel blockers, antiarrhythmic agents, centrally acting antihypertensive drugs, insulin, anticonvulsants, etc. Especially, intravenous administration of verapamil is prohibited due to the possibility of serious side effects. Pregnant or nursing women should not take this medication, and safety in children under 18 years is not established, therefore, it is not recommended. Elderly patients should start at a low dose and be closely monitored during treatment. In the case of overdose, bradycardia, hypotension, bronchospasm, or heart failure may occur, and immediate medical attention is necessary. Treatment may include gastric lavage, atropine administration, and plasma substituting agents as necessary, and specialized cardiac treatment may be required in severe cases.

Side effects

  • Rash
  • vision impairment
  • bradycardia
  • AV block
  • AV conduction delay
  • hypotension
  • heart failure
  • intermittent claudication
  • headache
  • dizziness
Show 91 more
  • paresthesia
  • depression
  • nightmares
  • syncope
  • diarrhea
  • constipation
  • nausea
  • dyspepsia
  • bloating
  • vomiting
  • shortness of breath
  • bronchospasm
  • pruritus
  • erythematous rash
  • exacerbation of psoriasis
  • edema
  • fatigue
  • erectile dysfunction
  • vascular neurogenic edema
  • hallucinations
  • psychosis
  • confusion
  • cyanotic extremities
  • dry eyes
  • Raynaud's phenomenon
  • dizziness
  • worsening of heart failure
  • orthostatic hypotension
  • drug intolerance
  • lower limb edema
  • chest discomfort
  • insomnia
  • palpitations
  • abdominal pain
  • frequent urination
  • elevated blood sugar
  • neck/shoulder pain
  • gastritis
  • chest pain
  • weakness
  • lack of effect
  • weight loss
  • cough
  • cold
  • dry cough
  • loss of appetite
  • anxiety
  • back pain
  • increased serum creatinine
  • tinnitus
  • vertigo
  • tremors
  • neuromuscular disease
  • gastroesophageal reflux
  • irritable bowel syndrome
  • thirst
  • gastric ulcer
  • gastrointestinal disorder
  • systemic weakness
  • facial edema
  • generalized edema
  • upper respiratory infection
  • rhinitis
  • sore throat
  • runny nose
  • agitation
  • drowsiness
  • arthralgia
  • flank pain
  • neck stiffness
  • low back pain
  • increased BUN
  • bladder discomfort
  • cystitis
  • urinary stones
  • hematuria
  • diabetes
  • urticaria
  • athlete's foot
  • sweating
  • tinea corporis
  • hypertension
  • cerebrovascular disease
  • peripheral vascular disease
  • flushing
  • epistaxis
  • increased ALT
  • increased AST
  • viral infection
  • thyroiditis
  • chronic myeloid leukemia

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly closed container to protect it from air and moisture. It is important to maintain the storage temperature between 1 and 30 degrees Celsius. Proper storage ensures the medication's effectiveness is preserved safely.

Appearance and packaging

Appearance

White round tablets

Package unit

30 tablets/bottle, 300 tablets/bottle, 500 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.